Latest news with #Revelation
Herald Malaysia
2 days ago
- General
- Herald Malaysia
A deep longing for unity
Reflecting on our Sunday Readings with Fr Sixtus Pitah OFM May 30, 2025 7th Sunday of Easter (C) Readings: Acts of the Apostle 7:55-60; Revelation 22:12-14, 16-17, 20; Gospel: John 17:20-26In today's readings, we hear a deep longing for unity — unity with God, unity with one another, and unity in truth and love. It's a unity that isn't abstract or just a nice spiritual idea. It's a unity born through real effort, real pain, and real faith — and it's what Jesus prays for before facing the Cross. St Stephen, in the First Reading, is being stoned to death. And yet, in the middle of that violence and hate, he gazes into heaven and sees Jesus. What does he do? He doesn't curse his killers. He doesn't beg for his life. Instead, he prays to be united with Jesus and even forgives those attacking him. That kind of faith, that kind of unity with Christ, is not soft or easy. It's costly. But it brings peace, not just to Stephen, but also — eventually — to a man named Saul, who stood there approving his death. Saul, who would become Paul, because of the witness of that unity. In the Gospel, Jesus prays for all of us — not just for His disciples at the Last Supper but for you and me today in our world, in our parishes, our BECs, our families. He says, "That they may be one, just as You, Father, are in Me, and I in You." Jesus wants our unity to reflect the same deep relationship of love within the Trinity — a unity rooted in self-giving, in listening, in mercy. But we live in a time where unity can be hard to be attained. There's just a lot of noise. We are constantly bombarded with messages online and in real life that divide: Us versus them. Right versus wrong. My truth versus your truth. And in this year's 59th World Communications Day, Pope Francis speaks right into this: he invites us to rediscover 'the language of the heart' — a way of communicating that brings people together instead of pushing them apart. He quotes St Paul: 'Speaking the truth in love' (Eph 4:15). That's not just about being nice. It's about learning how to speak with truth and tenderness. And more importantly, how to listen — to listen deeply, patiently, humbly. Pope Francis reminds us that 'listening is the first act of communication.' In our homes, in our WhatsApp groups, on Facebook, at the Mamak's shop or Kopitiam — are we listening? Or just reacting? In Malaysia, where we live side by side with people of many races, cultures, and beliefs, unity is not an ideal. It's a necessity. And as Christians, we are called to be a sign of that unity — not by force or pretending we are all the same, but by loving sincerely, communicating respectfully, and living with open hearts. The Pope also warns us about artificial intelligence — not in fear, but with caution. He reminds us that while technology can help us communicate faster, it cannot replace the warmth of human connection. He says: 'Machines can imitate us, but they cannot feel with us.' That's such an important reminder — especially for young people glued to screens. Real unity requires real people. Real encounters. Real hearts. As we approach Pentecost next week, we remember how the Holy Spirit united people who spoke different languages. Not by making them the same, but by helping them understand one another. That's the kind of unity we are invited into. Not uniformity, but harmony. So today, let's take Jesus' prayer seriously. Let's be people who don't just consume messages but communicate life. Let's speak with our hearts, forgive like Stephen, listen like Jesus, and build unity wherever we are — in our families, our parish, our communities, and even online. And maybe, like the final words of Revelation say, our hearts too can cry out: 'Come, Lord Jesus!' — not because the world is perfect, but because we long for the unity He brings. 'Unity begins with one open heart willing to love beyond comfort.' May that heart be ours today. Friar Sixtus Peter, OFM is the Vice Chairman of the Episcopal Regional Commission for Social Communications (ERCSC) Catholic Bishops' Conference of Malaysia, Singapore and Brunei (CBCMSB)
Digital Trends
2 days ago
- Entertainment
- Digital Trends
Did the Knives Out 3 teasers secretly reveal the Netflix release date?
Detective Benoit Blanc will return for another mystery in Wake Up Dead Man: A Knives Out Mystery. Netflix has now released two ominous teasers for Knives Out 3, and both might have revealed the release date. The first teaser is set to mysterious music and features brief footage of a church. The church's bell can be heard throughout the 12-second clip. The interesting part of the teaser lies in the caption, which reads, 'The wicked desire the stronghold of evildoers, but the root of the righteous endures.' The caption is a Bible verse from Proverbs 12:12. 'The wicked desire the stronghold of evildoers, but the root of the righteous endures.' — Wake Up Dead Man: A Knives Out Mystery (@KnivesOut) May 28, 2025 The setting of the second teaser is a graveyard that zeroes in on a cross. The caption reads, 'The devil has gone down to you! He is filled with fury, because he knows that his time is short.' This Bible verse is Revelation 12:12. 'The devil has gone down to you! He is filled with fury, because he knows that his time is short.' — Wake Up Dead Man: A Knives Out Mystery (@KnivesOut) May 29, 2025 It can't be a coincidence that the two Bible verses come from the 12th chapter and verse. 12:12 could mean December 12. With Knives Out 3 premiering in 2025, December 12 is a Friday, the day of the week when Netflix releases its marquee original movies. Recommended Videos The Knives Out franchise has previously released films in Q4 of the year, meaning a December 2025 release date for Knives Out 3 makes sense. Knives Out premiered in November 2019, and Glass Onion: A Knives Out Mystery streamed in December 2022. Knives Out maestro Rian Johnson returns to write, direct, and produce Wake Up Dead Man. Daniel Craig reprises his role as Blanc for the third time. Like the previous two films, Knives Out 3 boasts a star-studded cast that includes Josh O'Connor, Glenn Close, Josh Brolin, Mila Kunis, Jeremy Renner, Kerry Washington, Andrew Scott, Cailee Spaeny, Daryl McCormack, and Thomas Haden Church. More information about Knives Out 3 could be revealed at Netflix Tudum 2025: The Live Event. Hosted by Sofia Carson, Tudum 2025 will feature appearances from Netflix's biggest stars as they tease upcoming movies and TV shows. Tudum could be the perfect launching pad for the Wake Up Dead Man release date. Tudum 2025 will stream live on Netflix at 8 p.m. ET/5 p.m. PT on May 31.
Yahoo
2 days ago
- Business
- Yahoo
Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering
SAN DIEGO, May 29, 2025--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the closing of its previously announced public offering of 3,640,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 14,560,000 shares of its common stock at an offering price to the public of $1.10 per share and associated warrant. The warrants will have an exercise price of $1.10 per share, are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants, and will expire five years following the initial exercise date. Roth Capital Partners acted as sole placement agent for the offering. The gross proceeds to the Company from the offering were approximately $4 million, before deducting the placement agent's fees and other offering expenses payable by Revelation. The Company intends to use the net proceeds from this offering to further the development of our product candidates, including (i) the completion of our ongoing Phase 1b clinical study, (ii) the manufacture of clinical drug supply, (iii) additional preclinical work for multiple indications, (iv) continue to develop other products and therapies, and (v) fund working capital and general corporate purposes using any remaining amounts. The securities described above were offered pursuant to a registration statement on Form S-1 (File No. 333-287423), as amended, that was declared effective by the U.S. Securities and Exchange Commission ("SEC"), on May 28, 2025. The offering was made solely by means of a prospectus. Copies of the accompanying prospectus relating to and describing the terms of the offering may be obtained at the SEC's website at or by contacting Roth Capital Partners, LLC, 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660 or by email at rothecm@ This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About Revelation Biosciences, Inc. Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease. For more information on Revelation, please visit Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation. View source version on Contacts Company Contacts Mike PorterInvestor Relations Porter LeVay & Rose mike@ Chester Zygmont, IIIChief Financial Officer Revelation Biosciences czygmont@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
2 days ago
- Business
- Business Wire
Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering
SAN DIEGO--(BUSINESS WIRE)-- Revelation Biosciences, Inc. (NASDAQ: REVB) (the 'Company' or 'Revelation'), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the closing of its previously announced public offering of 3,640,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 14,560,000 shares of its common stock at an offering price to the public of $1.10 per share and associated warrant. The warrants will have an exercise price of $1.10 per share, are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants, and will expire five years following the initial exercise date. Roth Capital Partners acted as sole placement agent for the offering. The gross proceeds to the Company from the offering were approximately $4 million, before deducting the placement agent's fees and other offering expenses payable by Revelation. The Company intends to use the net proceeds from this offering to further the development of our product candidates, including (i) the completion of our ongoing Phase 1b clinical study, (ii) the manufacture of clinical drug supply, (iii) additional preclinical work for multiple indications, (iv) continue to develop other products and therapies, and (v) fund working capital and general corporate purposes using any remaining amounts. The securities described above were offered pursuant to a registration statement on Form S-1 (File No. 333-287423), as amended, that was declared effective by the U.S. Securities and Exchange Commission ('SEC'), on May 28, 2025. The offering was made solely by means of a prospectus. Copies of the accompanying prospectus relating to and describing the terms of the offering may be obtained at the SEC's website at or by contacting Roth Capital Partners, LLC, 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660 or by email at rothecm@ This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About Revelation Biosciences, Inc. Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease. For more information on Revelation, please visit Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
Yahoo
2 days ago
- Business
- Yahoo
Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering
SAN DIEGO, May 29, 2025--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the pricing of a public offering of 3,640,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 14,560,000 shares of its common stock at an offering price to the public of $1.10 per share and associated warrant. The warrants will have an exercise price of $1.10 per share, are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants, and will expire five years following the initial exercise date. The closing of the offering is expected to occur on or about May 29, 2025, subject to the satisfaction of customary closing conditions. Roth Capital Partners is acting as sole placement agent for the offering. The gross proceeds to the Company from the offering are expected to be approximately $4 million, before deducting the placement agent's fees and other offering expenses payable by Revelation. The Company intends to use the net proceeds from this offering to further the development of our product candidates, including (i) the completion of our ongoing Phase 1b clinical study, (ii) the manufacture of clinical drug supply, (iii) additional preclinical work for multiple indications, (iv) continue to develop other products and therapies, and (v) fund working capital and general corporate purposes using any remaining amounts. The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-287423), as amended, that was declared effective by the U.S. Securities and Exchange Commission ("SEC"), on May 28, 2025. The offering is being made solely by means of a prospectus. Copies of the accompanying prospectus relating to and describing the terms of the offering may be obtained, when available, at the SEC's website at or by contacting Roth Capital Partners, LLC, 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660 or by email at rothecm@ This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About Revelation Biosciences, Inc. Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease. For more information on Revelation, please visit Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation. View source version on Contacts Company Contacts Mike PorterInvestor Relations Porter LeVay & Rose mike@ Chester Zygmont, IIIChief Financial Officer Revelation Biosciences czygmont@
